Nasdaq: Praxis Precision Medicines to Present Late-Stage Data on CNS Disorders at AAN 2025 Annual Meeting Praxis Precision Medicines to Present Late-Stage Data on CNS Disorders at AAN 2025 Annual Meeting Business Wire: Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics is launching to create the next generation of regenerative medicines to restore hope for people affected by CNS disorders. The company has completed a ... Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders Business Wire: Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders The central nervous system (CNS) critically depends on the integrity of oligodendrocytes, specialised glial cells responsible for the formation and maintenance of myelin sheaths.
